A Phase II, Opened, Not Controlled and Multicentric Clinical Trial of Pazopanib in Monotherapy to Determine Efficiency and Safety in Second-line of Treatment in Patients With Carcinoma of Advanced Renal Cells That Have Progressed or Have Not Tolerated the First Line of Treatment With Tyrosine Kinase Inhibitor

Trial Profile

A Phase II, Opened, Not Controlled and Multicentric Clinical Trial of Pazopanib in Monotherapy to Determine Efficiency and Safety in Second-line of Treatment in Patients With Carcinoma of Advanced Renal Cells That Have Progressed or Have Not Tolerated the First Line of Treatment With Tyrosine Kinase Inhibitor

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 28 Jun 2012 New source identified: European Clinical Trials Database record (EudraCT2011-002441-34) integrated.
    • 23 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top